These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

155 related articles for article (PubMed ID: 7034658)

  • 1. Clinical studies of a perfluorochemical whole blood substitute (Fluosol-DA) Summary of 186 cases.
    Mitsuno T; Ohyanagi H; Naito R
    Ann Surg; 1982 Jan; 195(1):60-9. PubMed ID: 7034658
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Present status of clinical studies of Fluosol-DA (20%) in Japan.
    Mitsuno T; Ohyanagi H
    Int Anesthesiol Clin; 1985; 23(1):169-84. PubMed ID: 3980104
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Development of a perfluorochemical whole blood substitute (Fluosol-DA, 20%)--an overview of clinical studies with 185 patients.
    Suyama T; Yokoyama K; Naito R
    Prog Clin Biol Res; 1981; 55():609-28. PubMed ID: 7027272
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The effects of fetal exchange transfusion with a red blood cell substitute.
    Ambrose A; Cefalo RC; Bowes WA
    Am J Obstet Gynecol; 1986 Mar; 154(3):667-74. PubMed ID: 3082209
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy of a blood substitute (Fluosol-DA, 20%) on cerebral ischemia.
    Oda Y; Handa H; Nagasawa S; Naruo Y; Asato R; Yonekawa Y
    Neurol Res; 1982; 4(1-2):35-45. PubMed ID: 6127644
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A perfluorochemical emulsion as an oxygen carrier.
    Yokoyama K; Suyama T; Okamoto H; Watanabe M; Ohyanagi H; Saitoh Y
    Artif Organs; 1984 Feb; 8(1):34-40. PubMed ID: 6703924
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Perfluorocarbons as blood substitutes: the early years. Experience with Fluosol DA-20% in the 1980s.
    Spence RK; Norcross ED; Costabile J; McCoy S; Cernaianu AC; Alexander JB; Pello MJ; Atabek U; Camishion RC
    Artif Cells Blood Substit Immobil Biotechnol; 1994; 22(4):955-63. PubMed ID: 7849967
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Fluosol-DA as a red-cell substitute in acute anemia.
    Gould SA; Rosen AL; Sehgal LR; Sehgal HL; Langdale LA; Krause LM; Rice CL; Chamberlin WH; Moss GS
    N Engl J Med; 1986 Jun; 314(26):1653-6. PubMed ID: 3713771
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effects of a transfusion with a blood substitute (Fluosol-DA, 20%) on cerebral circulation in the monkey.
    Nagasawa S; Handa H; Naruo Y; Oda Y; Yonekawa Y; Takebe Y
    Neurol Res; 1981; 3(3):237-50. PubMed ID: 6122175
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Hemodynamic and oxygen transport effects of a perfluorochemical blood substitute, fluosol-DA (20%).
    Tremper KK; Lapin R; Levine E; Friedman A; Shoemaker WC
    Crit Care Med; 1980 Dec; 8(12):738-41. PubMed ID: 7449405
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Development of a perfluorochemical emulsion as a blood gas carrier.
    Mitsuno T; Ohyanagi H; Yokoyama K
    Artif Organs; 1984 Feb; 8(1):25-33. PubMed ID: 6422912
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The influence of oxygenation on the 19F spin-lattice relaxation rates of fluosol-DA.
    Reid RS; Koch CJ; Castro ME; Lunt JA; Treiber EO; Boisvert DJ; Allen PS
    Phys Med Biol; 1985 Jul; 30(7):677-86. PubMed ID: 4023055
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Development and clinical application of perfluorochemical artificial blood.
    Ohyanagi H; Saitoh Y
    Int J Artif Organs; 1986 Sep; 9(5):363-8. PubMed ID: 3781670
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Perfluorochemical emulsion oxygen transport fluids: a clinical review.
    Tremper KK; Anderson ST
    Annu Rev Med; 1985; 36():309-13. PubMed ID: 3888055
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Fluosol DA-20% in treatment of severe anemia: ongoing studies in 52 patients.
    Spence RK; McCoy S; Costabile J; Norcross ED; Pello M; Alexander J; Atabek U; Wisdom C; Camishion R
    Biomater Artif Cells Immobilization Biotechnol; 1992; 20(2-4):1069. PubMed ID: 1391428
    [No Abstract]   [Full Text] [Related]  

  • 16. Plasma-mediated alterations of erythrocyte deformability by perfluorochemical blood substitutes.
    Holloway GM; O'Rear EA; Fung BM
    Blood; 1986 Jan; 67(1):173-6. PubMed ID: 3940545
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pulmonary complications after Fluosol administration to patients with life-threatening blood loss.
    Police AM; Waxman K; Tominaga G
    Crit Care Med; 1985 Feb; 13(2):96-8. PubMed ID: 3967511
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Red blood cell substitutes and artificial blood.
    Bowman RJ
    Hum Pathol; 1983 Mar; 14(3):218-20. PubMed ID: 6832769
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Recent studies on perfluorochemical (PFC) emulsion as an oxygen carrier in Japan.
    Mitsuno T; Ohyanagi H; Yokoyama K; Suyama T
    Biomater Artif Cells Artif Organs; 1988; 16(1-3):365-73. PubMed ID: 3052644
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Hypotensive reaction after infusion of a perfluorochemical emulsion.
    Waxman K; Cheung CK; Mason GR
    Crit Care Med; 1984 Jul; 12(7):609-10. PubMed ID: 6610534
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.